Givinostat

• A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD P… Recruiting
  2024-511823-32-00 Phase II 3 countries Italfarmaco S.p.A.
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 Phase III 11 countries Italfarmaco S.p.A.
• Randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety and tolerability of givinostat in non-ambul… Recruiting
  2023-503521-19-00 Phase III 9 countries Italfarmaco S.p.A.
• Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy… Recruiting
  2023-504520-26-00 Phase III 6 countries Italfarmaco S.p.A.
• Long-term study evaluating the effect of givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms Ended
  2024-512413-40-00 Phase II 1 country Italfarmaco S.p.A.

Showing 1–5 of 5 trials